A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trial
Funding sources: The PEARL study was supported by Janssen Research & Development, LLC, a Johnson & Johnson pharmaceutical company, Spring House, PA, U.S.A.
Conflicts of interest: T-F.T. has conducted clinical trials or received honoraria for serving as a consultant for Wyeth Pharmaceuticals (now Pfizer Inc.), Serono International SA (now Merck Serono SA), Uni-Pharma/Biogen Idec and Janssen-Cilag Pharmaceuticals, and has received speaking fees from Abbott Laboratories. H-Y.C. has no conflicts of interest to declare. M.S. and D.C. are employees of Janssen Biotech, Inc., Spring House, PA, U.S.A., and own stock in the parent company, Johnson & Johnson.
No abstract is available for this article.